And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, we are happy to say, is rather modest. We look forward to hanging with a short person or two, catching up on our reading, puttering around the castle, and playing a few favorite melodies. And what about you? This remains a fine time to enjoy the great outdoors. You could make time for someone special. Or perhaps this is an opportunity to purchase a costume for a spooky day that is just around the corner. Feel free to write us for suggestions. Well, whatever you do, have a grand time. Enjoy, but be safe. And see you soon …

A report by the Congressional Research Services indicates the drug pricing bill pushed by House Democrats could run afoul of not one, not two, but three separate parts of the U.S. Constitution, STAT reports. At least one Republican has already seized on this new report — at another committee meeting this week, he held it up as a reason to slow down consideration of H.R. 3. The legislation is likely headed for a floor vote next month. The bad news for Democrats is that the potential constitutional issues with the bill can’t be fixed with a few tweaks.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy